You have 9 free searches left this month | to do more

ofatumumab

Ofatumumab is a drug used to treat Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Arthritis, Rheumatoid, and other conditions. Ofatumumab is being actively studied in 23 studies and prior, has been studied in 43.

Top SponsorsTop SitesTop Investigators
Novartis PharmaceuticalsNovartis Investigative SiteGian Marco Ghiggeri MD, PhD
GlaxoSmithKlineGSK Investigational SiteJennifer R. Brown, MD, PhD
M.D. Anderson Cancer CenterM D Anderson Cancer CenterC. Babis Andreadis
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2022-03-18
Mar 18, 2022
U
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ofatumumab
  • Los Angeles, California
    University of Southern California
2022-02-03
Feb 3, 2022
N
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis - 2021
Terminated
  • Relapsing Forms of Multiple Sclerosis
  • Lutherville, Maryland
  • +1 more
2022-02-28
Feb 28, 2022
M
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ofatumumab
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-02-23
Feb 23, 2022
N
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Recruiting
  • Relapse Remitting Multiple Sclerosis
  • Ofatumumab
  • Knoxville, Tennessee
    Novartis Investigative Site
2022-02-28
Feb 28, 2022
N
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Recruiting
  • Relapsing-Remitting Multiple Sclerosis
  • Ofatumumab
  • Disease modifying treatment (DMT)
  • Knoxville, Tennessee
    Novartis Investigative Site
2022-04-05
Apr 5, 2022
H
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
Active, not recruiting
Has Results
  • Chronic Graft Versus Host Disease
  • Ofatumumab
  • Phoenix, Arizona
  • +3 more
2021-11-15
Nov 15, 2021
M
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Active, not recruiting
  • Leukemia
  • Lymphoma
  • Ofatumumab
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-07-30
Jul 30, 2021
B
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
Recruiting
  • Relapsing Multiple Sclerosis
  • Boston, Massachusetts
    Partners MS Center, 60 Fenwood Road
2021-07-20
Jul 20, 2021
N
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab - 2020
Completed
Has Results
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Matching placebo of ofatumumab
  • Toon-city, Ehime, Japan
  • +13 more
2021-12-02
Dec 2, 2021
N
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Ofatumumab
  • +2 more
  • Phoenix, Arizona
  • +3 more
2022-01-19
Jan 19, 2022
N
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Recruiting
  • Multiple Sclerosis
  • Ofatumumab
  • Berlin, Germany
  • +7 more
2021-11-10
Nov 10, 2021
N
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Recruiting
  • Relapsing Multiple Sclerosis
  • Quadrivalent influenza vaccine
  • Ofatumumab
  • Phoenix, Arizona
  • +3 more
2021-08-30
Aug 30, 2021
D
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-08-09
Aug 9, 2021
H
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) - 2020
Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-04-02
Apr 2, 2021
N
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Active, not recruiting
Has Results
  • Small Lymphocytic Lymphoma
  • CLL (Chronic Lymphocytic Leukemia)
  • Fludarabine Phosphate
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-06
Apr 6, 2022
P
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients - 2018
Completed
  • Diffuse Large B Cell Lymphoma
  • Ofatumumab
  • +7 more
  • Wrocław, Dolnośląskie, Poland
  • +7 more
2021-12-23
Dec 23, 2021
R
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Active, not recruiting
Has Results
  • Stage I Mantle Cell Lymphoma
  • +4 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Buffalo, New York
  • +1 more
2022-03-09
Mar 9, 2022
N
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
Recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Birmingham, Alabama
  • +16 more
2022-03-22
Mar 22, 2022
N
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
  • Multiple Sclerosis (MS)
  • Tampa, Florida
  • +31 more
2022-04-05
Apr 5, 2022
G
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) - 2020
Completed
  • Chronic Lymphocytic Leukemia
  • Cologne, Germany
    German CLL Study Group
2020-06-09
Jun 9, 2020
I
Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome - 2019
Terminated
  • Nephrotic Syndrome
  • Ofatumumab
  • Placebo
  • Genoa, Italy/GE, Italy
    IRCCS Istituto Giannina Gaslini
2020-07-28
Jul 28, 2020
I
Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome - 2019
Completed
  • Nephrotic Syndrome
  • Genoa, Italy/GE, Italy
    IRCCS Istituto Giannina Gaslini
2020-07-28
Jul 28, 2020
M
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas - 2019
Completed
Has Results
  • Lymphoma
  • Ofatumumab
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2020-06-19
Jun 19, 2020
N
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
Recruiting
  • Multiple Sclerosis
  • Ofatumumab
  • First line DMT
  • Bayonne, Bayonne Cedex, France
  • +33 more
2022-03-25
Mar 25, 2022